<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/B6FB652A-60C3-48DD-9A33-075D1F759B48"><gtr:id>B6FB652A-60C3-48DD-9A33-075D1F759B48</gtr:id><gtr:name>University of Warwick</gtr:name><gtr:department>Biological Sciences</gtr:department><gtr:address><gtr:line1>Warwickshire</gtr:line1><gtr:line4>Coventry</gtr:line4><gtr:line5>West Midlands</gtr:line5><gtr:postCode>CV4 7AL</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/B6FB652A-60C3-48DD-9A33-075D1F759B48"><gtr:id>B6FB652A-60C3-48DD-9A33-075D1F759B48</gtr:id><gtr:name>University of Warwick</gtr:name><gtr:address><gtr:line1>Warwickshire</gtr:line1><gtr:line4>Coventry</gtr:line4><gtr:line5>West Midlands</gtr:line5><gtr:postCode>CV4 7AL</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/3B997AEA-AD1D-4C85-BFEF-99DFE51F3E6B"><gtr:id>3B997AEA-AD1D-4C85-BFEF-99DFE51F3E6B</gtr:id><gtr:firstName>Anthony</gtr:firstName><gtr:otherNames>Colin</gtr:otherNames><gtr:surname>Marriott</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/E97A4212-56ED-4B9F-A513-67FAEDC0AAB1"><gtr:id>E97A4212-56ED-4B9F-A513-67FAEDC0AAB1</gtr:id><gtr:firstName>Nigel</gtr:firstName><gtr:otherNames>John</gtr:otherNames><gtr:surname>Dimmock</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/BC293ADF-7C59-4CD2-875A-55E6E6654EEC"><gtr:id>BC293ADF-7C59-4CD2-875A-55E6E6654EEC</gtr:id><gtr:firstName>Andrew</gtr:firstName><gtr:otherNames>John</gtr:otherNames><gtr:surname>Easton</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0600832"><gtr:id>D0D23B36-167A-4167-A798-CE5C27457B96</gtr:id><gtr:title>Properties and in vivo mechanism(s) of action of cloned influenza virus interfering RNA - a new type of antiviral agent</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0600832</gtr:grantReference><gtr:abstractText>Influenza represents a continuing threat to human health. It has long been known that viruses containing genomes which have been significantly deleted can interfere with the replication of fully infectious virus. We have generated a specific interfering virus using molecular cloning techniques. Studies in mice have shown that exposure to this interfering virus does not generate disease but confers protection against a range of different influenza viruses. We intend to characterise the nature of the interfering virus genome and investigate the mechanism by which the interfering virus works. We will also study some fundamental characteristics of the interfering virus to determine the optimal method of production and stability. The interfering virus is a new approach to generating antiinfluenza drugs and, if successful, this would offer protection against a wide range of different strains, potentially including avian influenza virus.</gtr:abstractText><gtr:technicalSummary>Deleted forms of influenza A virus genome RNA segments which retain replication and packaging signals are packaged into virions when present in cells together with fully infectious virus. The deleted RNA interferes with the production of fully infectious virus in vitro and in vivo by an unknown mechanism and is termed interfering RNA (iRNA), and the particles which contain it are called interfering virus. In vivo, iRNA prophylactically protects mice and ferrets from clinical influenza. This protection is active against several different influenza subtypes, and is thus independent of the antigenicity of their surface proteins. We have cloned three iRNAs derived from influenza virus genome segment 1 and can make large amounts of cloned interfering virus in embryonated hen?s eggs. The different cloned interfering viruses protect mice from a lethal influenza challenge to different degrees. Using the cloned iRNA we intend to determine how influenza iRNAs effect protection. Possible mechanisms include iRNA-vRNA competition for a limiting essential replication factor; induction of alpha/beta interferon by iRNA; and, least likely, the creation of siRNAs from iRNA. None of these mechanisms is exclusive, and it may be that different iRNAs differ quantitatively or even qualitatively in their action. Data gained in this study will inform the potential of iRNAs for combating influenza in humans, birds and other animals, and open the way to human clinical trials.</gtr:technicalSummary><gtr:fund><gtr:end>2010-05-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2007-06-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>614257</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>disseminating information about the project</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>F4668D96-64FF-4728-8E31-854BB4540E5C</gtr:id><gtr:impact>Generatiuon of a podcast: http://www2.warwick.ac.uk/newsandevents/audio/?podcastItem=flu.mp3 and a Youtube video: http://www.youtube.com/watch?v=7FIVak0njIQ

This has generated interest in the antivial approach being investigated in the project. The You Tube clip has had 627 hits</gtr:impact><gtr:outcomeId>6D4082E6058</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Interviews on influenza virus :  print and other media</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>453FBE7A-1274-4D88-BA63-270DD6146341</gtr:id><gtr:impact>Approximately 40 interviews on radio and television on the influenza threat and treatment in 009. These were mostly in the UK but also New Zealand and California. Interviews with approximately 7press agencies. These and interviews for national and international newspapers led to more than 70 articles in the press worldwide and articles in more than 20 web-based news sites.
Contributed to two television programmes in 2012 discussing and demonstrating respiratory virus transmission in school children.
Approximately 10 interviews in 2014 leading to articles published in the media

This has increased the appreciation of the general public of aspects of influenza virus disease, transmission and prevention</gtr:impact><gtr:outcomeId>30D808782BB</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2009,2012,2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Alumni open day</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>017C282B-BD16-47A7-8FF5-BEDC2D8ED926</gtr:id><gtr:impact>An open day for alumni of the Department was held at whcih the current research was proesented in association with a poster.

At the time of the open day the public perception of the influenza pandemic and potential treatments was informed by the conventional media. This opportunity broadened the knowledge of attendees.</gtr:impact><gtr:outcomeId>99ABF428888</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Departmental open day</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>681D8C5F-9CB7-42A2-9241-66DD5FBD4137</gtr:id><gtr:impact>A formal open day was presented at whcih the research work carried out in the project was presented in association with a poster presentation.

This exercise was designed to increase applications for places to study at Warwick. The number of applications to courses has shown a significant increase.</gtr:impact><gtr:outcomeId>17653D31208</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2008,2009</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>The discovery shows that a defective virus derived from influenza can provide protection from infection with an unrelated respiratory virus.</gtr:description><gtr:grantRef>G0600832</gtr:grantRef><gtr:id>D4B004D2-38AB-4650-83F0-A00238C46D8C</gtr:id><gtr:impact>The discovery has shown that defective influenza viruses can induce interferon in vivo. This is able to provede protection from infection by interferon sensitive viruses. In addition the defective influenza is able to confer both prohylactic and therapeutic protection from influenza virus infection.</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>9F7390CA716</gtr:outcomeId><gtr:patentId>US2007202492</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Antiviral protection with viruses containing defective genome segments US2007202492 (A1)</gtr:title><gtr:yearProtectionGranted>2007</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:description>The product can be used prophylactically or therapeutically to prvent influenza virus infection or to reduce the severity of syptms of disease. In additon, it can provide short term protection from infection with other respiratory viruses</gtr:description><gtr:id>B3574A66-0BAD-4B85-B829-55877B86322F</gtr:id><gtr:impact>This product will be developed further in other animal specises to demonstrate broad proof of principle.</gtr:impact><gtr:outcomeId>FB73B47C815</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>influenza antiviral</gtr:title><gtr:type>Therapeutic Intervention - Vaccines</gtr:type><gtr:yearDevCompleted>2009</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>New fully chracterised defective interfering viruses have been generated. A study of receptor specificity has allowed thse to be targetted for specific receptor types.</gtr:description><gtr:id>9343AA57-3ABF-4446-A804-2F94DC39707F</gtr:id><gtr:impact>This has demonstrated that influenza DI viruses in which segment 3 has been deleted are capable of protection from flu infection in vivo.</gtr:impact><gtr:outcomeId>C5F11EB5F67</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>defective interfering virus</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>B1CF5CC2-E293-49C7-85A3-5EF6A3AEA0A5</gtr:id><gtr:title>Defective interfering viruses and their potential as antiviral agents.</gtr:title><gtr:parentPublicationTitle>Reviews in medical virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/92eaded1a07a59fb7e389434d308ccd0"><gtr:id>92eaded1a07a59fb7e389434d308ccd0</gtr:id><gtr:otherNames>Marriott AC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1052-9276</gtr:issn><gtr:outcomeId>3D699405DDB</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>98DDA5AE-4A69-45C5-975F-7BD1E67F0511</gtr:id><gtr:title>A Defective Interfering Influenza RNA Inhibits Infectious Influenza Virus Replication in Human Respiratory Tract Cells: A Potential New Human Antiviral.</gtr:title><gtr:parentPublicationTitle>Viruses</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2a2dbbe69cc9fd409a6a04eaf7bfd66a"><gtr:id>2a2dbbe69cc9fd409a6a04eaf7bfd66a</gtr:id><gtr:otherNames>Smith CM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1999-4915</gtr:issn><gtr:outcomeId>58c68987cb0852.78743858</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>996DCCE8-2532-4392-B3CE-7DB5FDE27B8E</gtr:id><gtr:title>Unexpected complexity in the interference activity of a cloned influenza defective interfering RNA.</gtr:title><gtr:parentPublicationTitle>Virology journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/26e2b0ef91980b521ba4025ee98b2093"><gtr:id>26e2b0ef91980b521ba4025ee98b2093</gtr:id><gtr:otherNames>Meng B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1743-422X</gtr:issn><gtr:outcomeId>5a2fd8f582a112.03813645</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8C74EA0C-8111-4B8C-83A2-F958755901FB</gtr:id><gtr:title>Defective interfering influenza virus confers only short-lived protection against influenza virus disease: evidence for a role for adaptive immunity in DI virus-mediated protection in vivo.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e47f93c88fb1b9cbf326342e600bea38"><gtr:id>e47f93c88fb1b9cbf326342e600bea38</gtr:id><gtr:otherNames>Scott PD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn><gtr:outcomeId>LMWvqu4sdkp</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>843FBE06-38BB-41F9-B45A-4835FCA0E230</gtr:id><gtr:title>The receptor preference of influenza viruses.</gtr:title><gtr:parentPublicationTitle>Influenza and other respiratory viruses</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/26e2b0ef91980b521ba4025ee98b2093"><gtr:id>26e2b0ef91980b521ba4025ee98b2093</gtr:id><gtr:otherNames>Meng B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1750-2640</gtr:issn><gtr:outcomeId>5DB2F47C000</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4B509DBF-A67F-406D-BDAD-3400053B4E12</gtr:id><gtr:title>Defective interfering influenza A virus protects in vivo against disease caused by a heterologous influenza B virus.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e47f93c88fb1b9cbf326342e600bea38"><gtr:id>e47f93c88fb1b9cbf326342e600bea38</gtr:id><gtr:otherNames>Scott PD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn><gtr:outcomeId>PFQYMMbw1TN</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>118A978A-5F77-46FD-A591-83A039018401</gtr:id><gtr:title>Defective interfering virus protects elderly mice from influenza.</gtr:title><gtr:parentPublicationTitle>Virology journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e47f93c88fb1b9cbf326342e600bea38"><gtr:id>e47f93c88fb1b9cbf326342e600bea38</gtr:id><gtr:otherNames>Scott PD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1743-422X</gtr:issn><gtr:outcomeId>YZrB2tqU7qu</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AA89BBE9-B00F-4745-BBB1-CBDCED5D1516</gtr:id><gtr:title>A novel broad-spectrum treatment for respiratory virus infections: influenza-based defective interfering virus provides protection against pneumovirus infection in vivo.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b3aaa1126b7e06b092ff1a2c4a12eb7c"><gtr:id>b3aaa1126b7e06b092ff1a2c4a12eb7c</gtr:id><gtr:otherNames>Easton AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn><gtr:outcomeId>S3vU5a1SdcX</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0600832</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>D8F3A27D-084A-40BB-A046-087DACE23410</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>3.4  Vaccines</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>